Hims & Hers Health, based in San Francisco, California, announced that it acquired Trybe Labs. The financial terms were not disclosed.
Trybe Labs, marketed as Sigmund NJ LLC, is an at-home lab testing facility. Its diagnostic testing abilities include a blood lancet, which is a less invasive alternative to traditional needles or dried blood spot cards. The technology allows customers to gain insights into their hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function and prostate health.
Hims & Hers is a multi-specialty telehealth platform that was founded in 2017. Hims & Hers provides personalized healthcare solutions by leveraging pharmacy operations to offer tailored treatments such as custom dosages, allergen-free medications and sterile compounded products.
This acquisition is set to introduce at-home lab testing capabilities to the Hims & Hers platform, which is expected to enhance personalized healthcare and treatment options for customers. The data gathered will also contribute to the company’s AI developments, including MedMatch by Hims & Hers, which aims to provide an AI-powered healthcare experience with affordable care tailored to individuals.
According to data captured in the LevinPro HC database, this transaction marks the 18th Laboratories, MRI and Dialysis acquisition of 2025, and the seventh in the diagnostic specialty. There were 63 diagnostic deals announced in both 2024 and 2023.
